Bixler Sandra L, Duplantier Allen J, Bavari Sina
United States Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Frederick, MD 21702 USA.
Curr Treat Options Infect Dis. 2017;9(3):299-317. doi: 10.1007/s40506-017-0130-z. Epub 2017 Aug 4.
Ebola virus, a member of the Filoviridae family, is a causative agent of severe viral hemorrhagic fever in humans. Over the past 40 years, the virus has been linked to several high mortality outbreaks in Africa with the recent West African outbreak resulting in over 11,000 deaths. This review provides a summary of the status of the drug discovery and development process for therapeutics for Ebola virus disease, with a focus on the strategies being used and the challenges facing each stage of the process.
Despite the wealth of in vitro efficacy data, preclinical data in animal models, and human clinical data, no therapeutics have been approved for the treatment of Ebola virus disease. However, several promising candidates, such as ZMapp and GS-5734, have advanced into ongoing clinical trials.
The gravity of the 2014-2016 outbreak spurred a heightened effort to identify and develop new treatments for Ebola virus disease, including small molecules, immunotherapeutics, host factors, and clinical disease management options.
Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endoresed by the U.S. Army.
埃博拉病毒是丝状病毒科的一员，是人类严重病毒性出血热的病原体。在过去40年里，该病毒与非洲几次高死亡率的疫情有关，最近的西非疫情导致超过11000人死亡。本综述总结了埃博拉病毒病治疗药物发现和开发过程的现状，重点关注所采用的策略以及该过程各阶段面临的挑战。
尽管有丰富的体外疗效数据、动物模型的临床前数据和人类临床数据，但尚无治疗药物被批准用于治疗埃博拉病毒病。然而，几种有前景的候选药物，如ZMapp和GS-5734，已进入正在进行的临床试验。
2014 - 2016年疫情的严重性促使人们加大力度识别和开发埃博拉病毒病的新治疗方法，包括小分子药物、免疫疗法、宿主因素和临床疾病管理方案。
观点、解释、结论和建议仅为作者所有，不一定得到美国陆军的认可。
